Brooks Sarah H, Klier Eliana M, Red Stuart D, Mehta Neeti D, Patel Saumil S, Chuang Alice Z, Suescun Jessika, Schiess Mya C, Sereno Anne B
Department of Cognitive Sciences, Rice University, Houston, TX, United States.
Department of Neurobiology and Anatomy, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Front Neurol. 2017 Jun 20;8:261. doi: 10.3389/fneur.2017.00261. eCollection 2017.
Current clinical diagnostic tools are limited in their ability to accurately differentiate idiopathic Parkinson's disease (PD) from multiple system atrophy (MSA) and other parkinsonian disorders early in the disease course, but eye movements may stand as objective and sensitive markers of disease differentiation and progression. To assess the use of eye movement performance for uniquely characterizing PD and MSA, subjects diagnosed with PD ( = 21), MSA ( = 11), and age-matched controls (C, = 20) were tested on the prosaccade and antisaccade tasks using an infrared eye tracker. Twenty of these subjects were retested ~7 months later. Saccade latencies, error rates, and longitudinal changes in saccade latencies were measured. Both PD and MSA patients had greater antisaccade error rates than C subjects, but MSA patients exhibited longer prosaccade latencies than both PD and C patients. With repeated testing, antisaccade latencies improved over time, with benefits in C and PD but not MSA patients. In the prosaccade task, the normal latencies of the PD group show that basic sensorimotor oculomotor function remain intact in mid-stage PD, whereas the impaired latencies of the MSA group suggest additional degeneration earlier in the disease course. Changes in antisaccade latency appeared most sensitive to differences between MSA and PD across short time intervals. Therefore, in these mid-stage patients, increased antisaccade errors combined with slowed prosaccade latencies might serve as a useful marker for early differentiation between PD and MSA, and, antisaccade performance, a measure of MSA progression. Together, our findings suggest that eye movements are promising biomarkers for early differentiation and progression of parkinsonian disorders.
目前的临床诊断工具在疾病早期准确区分特发性帕金森病(PD)与多系统萎缩(MSA)及其他帕金森氏症方面能力有限,但眼球运动可能是疾病鉴别和进展的客观且敏感的标志物。为了评估眼球运动表现用于独特表征PD和MSA的情况,使用红外眼动仪对诊断为PD(n = 21)、MSA(n = 11)和年龄匹配的对照组(C,n = 20)的受试者进行了前扫视和反扫视任务测试。其中20名受试者在约7个月后进行了重新测试。测量了扫视潜伏期、错误率以及扫视潜伏期的纵向变化。PD和MSA患者的反扫视错误率均高于C组受试者,但MSA患者的前扫视潜伏期比PD和C组患者均更长。随着重复测试,反扫视潜伏期随时间改善,C组和PD组患者有改善,但MSA患者没有。在前扫视任务中,PD组的正常潜伏期表明中期PD患者的基本感觉运动性眼球运动功能保持完好,而MSA组潜伏期受损表明在疾病进程中更早出现了额外的退化。反扫视潜伏期的变化在短时间间隔内对MSA和PD之间的差异似乎最为敏感。因此,在这些中期患者中,反扫视错误增加与前扫视潜伏期减慢可能是PD和MSA早期鉴别的有用标志物,并且反扫视表现可作为MSA进展的一项指标。总之,我们的研究结果表明眼球运动是帕金森氏症早期鉴别和进展的有前景的生物标志物。